By Sabela Ojea Shares of Protagonist Therapeutics on Wednesday rose 5.6% to $26.41 in post-market trading after the company signed a worldwide license and collaboration agreement with Takeda.
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset libyannewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from libyannewswire.com Daily Mail and Mail on Sunday newspapers.
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)Takeda Will Make.
Protagonist Therapeutics' rusfertide could have preliminary data next year from its Phase 3 test in polycythemia vera. If the peptide drug wins FDA approval in this rare blood disorder, the partners will share in U.S. commercialization while Takeda is responsible for the drug in the rest of the world.
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.